Fevipiprant, which targets PTGDR2, has been evaluated in clinical trials for asthma and atopic dermatitis; Zileuton, a 5-lipoxygenase inhibitor that reduces leukotriene synthesis, targets ALOX5; and captopril, an angiotensin-converting enzyme inhibitor, targets ACE. This evidence concerns the gene ACE and atopic eczema.